secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0000950170-23-040608
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenon reports Q2 net loss $47.5M; XEN1101 MDD trial fully enrolled with data expected late Nov-Dec
--------------------------------------------------------------------------------

- Q2 net loss $47.5M vs $31.2M YoY; R&D expenses doubled to $44.0M on XEN1101 Phase 3 and MDD trials.
- Cash $652.2M (down from $720.8M); sufficient to fund operations into 2026.
- Last patient enrolled in XEN1101 Phase 2 X-NOVA MDD trial; topline data expected late Nov to mid-Dec 2023.
- Phase 3 epilepsy trials X-TOLE2/3 and X-ACKT continue; partnered NBI-921352 Phase 2 data expected Q4 2023.
- Webinar on MDD mechanism and X-NOVA design scheduled for mid-September.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000095017023040608/0000950170-23-040608-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000095017023040608/xene-20230809.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-040608

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer